In a quest to augment its blockbuster cancer drug Keytruda, Merck is tapping Moderna, a controversial Cambridge, Mass.-based biotech, to develop an anti-cancer vaccine that targets one of the toughest targets in drug development.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,